Xenon to Present at Upcoming Investor Conferences
Globe Newswire•03/11/2026•16:01 ET
0
Key Highlights
- ➤Xenon (XENE) will present at four investor conferences in Q4 2026
- ➤Azetukalner remains in late-stage development for epilepsy and mood disorders
- ➤Xenon is advancing Phase 1 K(V)7 and Na(V)1.7 pain programs
VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the fourth quarter of 2026. * Guggenheim 3(rd) Annual Healthcare Innovation Conference, Boston, MA Fireside chat: Tuesday, November 10, 2026, 2:30–2:55pm EST
* Stifel 2026 Healthcare Conference, New York, NY Fireside chat: Wednesday, November 11, 2026, 4:40–5:10pm EST
Get started
Create a free account to read the full story.